920 related articles for article (PubMed ID: 15258107)
1. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
2. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
3. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
Liu KH; Kim MJ; Shon JH; Moon YS; Seol SY; Kang W; Cha IJ; Shin JG
Xenobiotica; 2005 Jan; 35(1):27-38. PubMed ID: 15788366
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
7. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Ko JW; Sukhova N; Thacker D; Chen P; Flockhart DA
Drug Metab Dispos; 1997 Jul; 25(7):853-62. PubMed ID: 9224780
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
10. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
11. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
15. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors and their drug interactions: an evidence-based approach.
Gerson LB; Triadafilopoulos G
Eur J Gastroenterol Hepatol; 2001 May; 13(5):611-6. PubMed ID: 11396546
[TBL] [Abstract][Full Text] [Related]
17. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
18. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
[TBL] [Abstract][Full Text] [Related]
19. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
20. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]